Abstract 229P
Background
Differences in treatment paradigms and prognosis based on tumor aggressiveness emphasized the urgent need to accurately detect muscle invasion of bladder cancer. DWI, based on the hypothesis that diffusion follows by Gaussian distribution, has shown great promise in differentiating MIBC and NMIBC. DKI is believed to better reflect the deviation from a Gaussian distribution due to irregularity and heterogeneity of cell microstructure and tissue components. Therefore, the present study was designed to quantitatively investigate the diagnostic performances of DKI in predicting aggressiveness of bladder cancer and to compare the potential of parameters obtained from DWI and DKI.
Methods
Multiple b value DWIs were performed using a 3.0-T magnetic resonance imaging unit in 61 patients with bladder cancer including MIBC and NMIBC confirmed by histopathological findings. DWI data were postprocessed using mono-exponential and DKI models to calculate the apparent diffusion coefficient, apparent diffusional kurtosis, and kurtosis-corrected diffusion coefficient. Receiver-operating characteristic analysis was performed to compare the diagnostic efficacy of all diffusion parameters. SPSS and MedCalc were used to perform the statistical analyses. ADC and DKI parameters were measured and processed using IMAge/enGINE MR_Diffusion (an open-source software).
Results
Both ADC and DKI values differed significantly between MIBC and NMIBC. The ADC and Dapp values of the MIBC group were lower than the NMIBC group (all p<0.001), whilst Kapp values were higher than those of the NMIBC group (p<0.001). The AUC values of ADC, Dapp and Kapp were 0.833, 0.859, and 0.920 for differentiating MIBC from NMIBC, respectively. The combination of Dapp and Kapp value had the highest AUC of 0.944. For pairwise comparisons of ROC curves, ADC was worse than Kapp (p=0.030), and worse than the combination of Dapp and Kapp (p=0.007). ADC was not significantly different from Dapp (p=0.528).
Conclusions
Both conventional DWI and DKI models are beneficial in differentiating between MIBC and NMIBC, whilst Kapp and the combination of Dapp and Kapp could produce more robust values than conventional ADC in evaluating aggressiveness of bladder cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Affiliated to Fudan University.
Funding
Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract